SeaStar Medical Holding Corporation (ICU) - Cash Flow Conversion Efficiency
Based on the latest financial reports, SeaStar Medical Holding Corporation (ICU) has a cash flow conversion efficiency ratio of -0.393x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.09 Million) by net assets ($10.42 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ICU net asset quality score to measure how much of total assets are equity-financed.
SeaStar Medical Holding Corporation - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how SeaStar Medical Holding Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check SeaStar Medical Holding Corporation (ICU) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
SeaStar Medical Holding Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SeaStar Medical Holding Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Immo Moury SICAF Immobiliere Publique de Droit Belge
BR:IMMOU
|
0.026x |
|
SBC Corp Bhd
KLSE:5207
|
-0.023x |
|
AIM Commercial Growth Freehold And Leasehold Real Estate Investment Trust
BK:AIMCG
|
0.005x |
|
Panca Global Securities Tbk
JK:PEGE
|
-0.129x |
|
Eagle Plains Resources Ltd.
V:EPL
|
-0.112x |
|
Olympia Industries Bhd
KLSE:3018
|
0.024x |
|
CSLM Acquisition Corp.
NASDAQ:CSLMF
|
-0.046x |
|
Waja Konsortium Bhd
KLSE:0102
|
-0.035x |
Annual Cash Flow Conversion Efficiency for SeaStar Medical Holding Corporation (2020–2025)
The table below shows the annual cash flow conversion efficiency of SeaStar Medical Holding Corporation from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see ICU market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $10.42 Million | $-13.60 Million | -1.306x | -117.81% |
| 2024-12-31 | $-2.18 Million | $-16.01 Million | 7.333x | +888.85% |
| 2023-12-31 | $-13.87 Million | $-10.29 Million | 0.742x | +97.53% |
| 2022-12-31 | $-20.76 Million | $-7.79 Million | 0.375x | -79.33% |
| 2021-12-31 | $-2.82 Million | $-5.11 Million | 1.816x | +2233.07% |
| 2020-12-31 | $-71.58 Million | $-5.57 Million | 0.078x | -- |
About SeaStar Medical Holding Corporation
SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperi… Read more